Lung Cancer Trials Ask AI to find trials
RecruitingPhase 3NCT06881784
Official study title

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Study summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studieddaraxonrasib and docetaxel

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 29, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 3

Interventional

Where is it offered?158 U.S. locations

Locations may change over time.

Who runs it?Revolution Medicines, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 3
Sponsor
Revolution Medicines, Inc.
Interventions being studied
Drug: daraxonrasib; Drug: docetaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.
  • Measurable disease per RECIST v1.1.
  • Adequate organ function (bone marrow, liver, kidney, coagulation).
  • One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy.
  • Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).
  • Able to take oral medications.
Reasons someone may not be able to joinExclusion criteria
  • Prior therapy with direct RAS-targeted therapy or docetaxel.
  • Untreated central nervous system (CNS) metastases.
  • Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).
  • Ongoing anticancer therapy.
  • Pregnant or breastfeeding.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Alabama OncologyBirmingham, Alabama
  • MemorialCare Long Beach Medical CenterLong Beach, California
  • Yale University, Smillow Cancer CenterNew Haven, Connecticut
  • Florida Cancer Specialists & Research Institute - SouthFort Myers, Florida
  • BRCR GlobalPlantation, Florida
  • Cancer Care Centers of BreevardRockledge, Florida
  • Florida Cancer Specialists & Research Institute - NorthSt. Petersburg, Florida
  • Cleveland Clinic Martin NorthStuart, Florida
  • Florida Cancer Specialists & Research Institute - EastWest Palm Beach, Florida
  • University Cancer and Blood CenterAthens, Georgia
  • Piedmont Healthcare, IncAtlanta, Georgia
  • Winship Cancer InstituteAtlanta, Georgia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 29, 2026. Always confirm current availability with the study team.

View original record ↗